Feasibility Study of Exenatide by Continuous Subcutaneous Infusion
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to investigate the feasibility of administering exenatide by
continuous subcutaneous infusion to healthy subjects. Study will consist of two parts i.e.
Part A and B. In Part A 2 healthy subjects will receive exenatide infusion over 24 hours
followed by a follow-up visit 10 to 14 days after discharge from clinic. In Part B
approximately 6 healthy subjects will receive subcutaneous infusions of exenatide for maximum
of 7 days followed by a follow-up visit 10 to 14 days after discharge from clinic.